前列腺健康指数在前列腺癌检测中的应用:来自大型学术实践的结果
在单一大型学术中心对345例接受前列腺癌诊断评估的患者检测前列腺健康指数(phi),并与1318例未检测phi的同期队列比较。phi对任何前列腺癌和GG≥2前列腺癌的预测均优于PSA,phi<19.6者无前列腺癌诊断,phi<27且PI-RADS≤3者无GG≥2癌症。phi检测使前列腺活检率降低9%(39% vs 48%,P<0.001),主要因阴性活检(8%)和GG1活检(1%)减少,而GG≥2癌症检出比例不变。
要点
- phi预测任何前列腺癌的AUC为0.72,优于PSA的0.47。
- phi预测GG≥2前列腺癌的AUC为0.77,优于PSA的0.53。
- phi<19.6者无前列腺癌诊断,phi<27者仅3例GG≥2癌症。
核心结论
- 在该大型实时临床经验中,phi优于单独PSA,与高级别前列腺癌相关,并为MRI提供补充信息。
- 将phi纳入临床实践减少了不必要活检率,而未改变高级别癌症的检出频率。
研究设计与样本
- 在单一大型学术中心,对345例接受前列腺癌诊断评估的患者检测phi,前瞻性记录前列腺活检(含Grade Group分级)、磁共振成像(MRI)和根治性前列腺切除术(RP)结果。
- 将活检率和结局与未检测phi的同期队列(n=1318)进行比较。
主要发现
- 总体39%的phi检测男性接受了前列腺活检。
- phi<19.6的男性无一诊断为前列腺癌,phi<27的男性中仅3例为GG≥2癌症。
- phi预测任何前列腺癌的AUC为0.72 vs PSA的0.47,预测GG≥2前列腺癌的AUC为0.77 vs PSA的0.53。
- 在接受MRI和phi的男性中,phi<27且PI-RADS≤3者无GG≥2癌症。
- 接受RP者中,phi升高与更高的病理GG(P=0.002)和分期(P=0.001)相关。
关键数值与推荐
- phi预测任何前列腺癌的AUC为0.72,PSA为0.47。
- phi预测GG≥2前列腺癌的AUC为0.77,PSA为0.53。
- phi<19.6者无前列腺癌诊断;phi<27者仅3例GG≥2癌症。
- phi<27且PI-RADS≤3者无GG≥2癌症。
- phi检测组活检率39% vs 未检测组48%(P<0.001),降低9%。
临床怎么用
- 原文结论认为phi优于单独PSA、与高级别前列腺癌相关并提供MRI补充信息。
- 原文结论认为将phi纳入临床实践可减少不必要活检而不改变高级别癌症检出频率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Prostate Health Index (phi) outperforms PSA and other PSA derivatives for the diagnosis of prostate cancer (PCa). The impact of phi testing in the real-world clinical setting has not been previously assessed. METHODS: In a single, large, academic center, phi was tested in 345 patients presenting for diagnostic evaluation for PCa. Findings on prostate biopsy (including Grade Group (GG), defined as GG1: Gleason score (GS) 6, GG2: GS 3+4=7, GG3: GS 4+3=7, GG4: GS 8 and GG5: GS 9-10), magnetic resonance imaging (MRI) and radical prostatectomy (RP) were prospectively recorded. Biopsy rates and outcomes were compared with a contemporary cohort that did not undergo phi testing (n=1318). RESULTS: Overall, 39% of men with phi testing underwent prostate biopsy. No men with phi<19.6 were diagnosed with PCa, and only three men with phi<27 had cancer of GG⩾2. Phi was superior to PSA for the prediction of any PCa (area under the receiver operating characteristic curve (AUC) 0.72 vs 0.47) and GG⩾2 PCa (AUC 0.77 vs 0.53) on prostate biopsy. Among men undergoing MRI and phi, no men with phi<27 and PI-RADS⩽3 had GG⩾2 cancer. For those men proceeding to RP, increasing phi was associated with higher pathologic GG (P=0.002) and stage (P=0.001). Compared with patients who did not undergo phi testing, the use of phi was associated with a 9% reduction in the rate of prostate biopsy (39% vs 48%; P<0.001). Importantly, the reduction in biopsy among the phi population was secondary to decreased incidence of negative (8%) and GG1 (1%) biopsies, whereas the proportion of biopsies detecting GG⩾2 cancers remained unchanged. CONCLUSIONS: In this large, real-time clinical experience, phi outperformed PSA alone, was associated with high-grade PCa, and provided complementary information to MRI. Incorporation of phi into clinical practice reduced the rate of unnecessary biopsies without changing the frequency of detection of higher-grade cancers.
引用
- Tosoian JJ, Druskin SC, Andreas D, et al. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate Cancer Prostatic Dis. 2017. PMID: 28117387. doi:10.1038/pcan.2016.72
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。